» Articles » PMID: 32185125

Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Mar 19
PMID 32185125
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Primary liver cancer is a leading cause of cancer deaths worldwide. Global burden varies, reflecting geographical distribution of viral hepatitis. Our objective was to perform a systematic review and meta-analysis of published current trends in incidence of adult liver cancers and histological types worldwide. This study used systematic searches of PubMed, Embase, CINAHL, and Web of Science databases for English-language peer-reviewed articles published from 1 January 2008 to 01 September 2019. Inclusion criteria were population-based studies of adult liver cancer patients with quantitative estimates of temporal trends in incidence for liver cancers and/or histological types. For multiple studies from the same geographical area, only the publication that reported the most recent trends for the same cancer type and population subgroup was included. Review was conducted per PRISMA guidelines. Two authors independently extracted data and critically assessed studies. Proposed contributors to observed trends were extracted from included articles. Study-specific estimates of the annual percentage change (APC) in incidence rates with 95% confidence intervals (CIs) were pooled using random-effects meta-analysis models. Heterogeneity was measured using the statistics and publication bias evaluated using funnel plots and Egger's tests. Overall, 53 studies met the inclusion criteria, of which 31 were included in the meta-analysis. Overall, pooled APC estimates were +0.8 (95% CI -0.3, +2.0) for liver cancers combined, +2.6 (95% CI +1.2, +4.0) for hepatocellular carcinoma (HCC), and +4.3 (95% CI +2.5, +6.1) for intrahepatic cholangiocarcinoma. Subgroup analyses indicated increasing trends for liver cancers (APC +3.2, 95% CI +2.5, +3.9) and HCC (APC +3.6, 95% CI +2.9, +4.4) in the region of North America/Europe/Australia, whereas corresponding trends were decreasing (APC -1.7, 95% CI -2.2, -1.1) and stable (APC -0.7, 95% CI -1.9, +0.5) in Asia, respectively. Incidence is increasing for adult liver cancers and HCC in Western countries, whereas trends are decreasing in the Asian region, although still remaining high. Our findings highlight the importance of viral hepatitis control and lifestyle interventions to reduce global liver cancer burden. Ongoing surveillance is also vital to detect early shifts in incidence trends.

Citing Articles

Global, regional and national burden of liver cancer 1990-2021: a systematic analysis of the global burden of disease study 2021.

Jiang Z, Zeng G, Dai H, Bian Y, Wang L, Cao W BMC Public Health. 2025; 25(1):931.

PMID: 40057711 PMC: 11890516. DOI: 10.1186/s12889-025-22026-6.


Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide population-based cohort study.

Chiu C, Hao W, Lin K, Chen C, Yang T, Fang Y BMC Gastroenterol. 2025; 25(1):109.

PMID: 39994561 PMC: 11849173. DOI: 10.1186/s12876-025-03665-w.


Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis.

Xuan W, Zhang X, Fang Y, Zhang Y, Xiang Z, Yu Y Oncol Lett. 2025; 29(3):122.

PMID: 39807096 PMC: 11726279. DOI: 10.3892/ol.2025.14868.


Complete Response with Immunotherapy Alone after Discontinuing VEGF Inhibitor in Advanced Hepatocellular Carcinoma: A Case Report.

Naviwala M, Shoaib D, Khan W, Zaki A Euroasian J Hepatogastroenterol. 2025; 14(2):246-250.

PMID: 39802858 PMC: 11714098. DOI: 10.5005/jp-journals-10018-1455.


Artificial intelligence: clinical applications and future advancement in gastrointestinal cancers.

Akbari A, Adabi M, Masoodi M, Namazi A, Mansouri F, Tabaeian S Front Artif Intell. 2025; 7:1446693.

PMID: 39764458 PMC: 11701808. DOI: 10.3389/frai.2024.1446693.


References
1.
Patel N, Benipal B . Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States. Cureus. 2019; 11(1):e3962. PMC: 6436669. DOI: 10.7759/cureus.3962. View

2.
Njei B, Rotman Y, Ditah I, Lim J . Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2014; 61(1):191-9. PMC: 4823645. DOI: 10.1002/hep.27388. View

3.
Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

4.
Ward E, Sherman R, Henley S, Jemal A, Siegel D, Feuer E . Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20-49 Years. J Natl Cancer Inst. 2019; 111(12):1279-1297. PMC: 6910179. DOI: 10.1093/jnci/djz106. View

5.
de Martel C, Maucort-Boulch D, Plummer M, Franceschi S . World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015; 62(4):1190-200. PMC: 5019261. DOI: 10.1002/hep.27969. View